Fibrinogen catabolism in systemic lupus erythematosus

Abstract

Because there is mounting evidence that localized intravascular coagulation maycontribute to tissue injury following a variety of immunologic events, including immune complex diseases, fibrinogen catabolism was studied in patients with systemic lupus erythematosus to determine factors correlating with accelerated coagulation. 125I‐fibrinogen half‐life in controls was 80.1 ± 11 hours and the mean SLE half‐life was 60.5 ± 12. SLE patients in complete clinical remission had normal half‐lives, but patients with symptomatic clinical disease, including renal disease, had significantly reduced fibrinogen survival. Accelerated fibrinogen consumption also correlated with positive tests for anti‐DNA antibodies, but not with hypocomplementemia. These observations support the hypothesis that the coagulation system is activated in patients with immune complex diseases. Further studies are required to define the role, if any, that coagulation may play in causing tissue injury.

Advanced oxidation protein products as a biomarker of cutaneous lupus erythematosus complicated by nephritis: a case-control study

“…Our recent study suggested that fibrinogen in plasma does not have the same biological features as AOPPs (Chen et al, 2011). Fibrinogen levels are elevated in SLE patients (Ames et al, 2000), while the half-life of plasma fibrinogen is decreased in SLE patients complicated with LN (Sergent et al, 1976). Therefore, fibrinogen might interfere with the applicability of AOPP levels in the evaluation of SLE activity, particularly in cases complicated by LN.…”

Disseminated Intravascular Coagulation in a Patient with Systemic Lupus Erythematosus with Lupus Anticoagulant.

“…However, the levels of fibrinogen and AT III are usually observed within the normal range or are slightly elevated in patients with TMA.Therefore, we diagnosed that she had DICbased on the fact that her clinical manifestations and laboratory findings fulfilled the criteria for DIC. Hematological abnormalities in SLE may be due to autoimmunemanifestations, such as circulating anticoagulants, CICs or vasculitis (1,(13)(14)(15). Although the development ofDIC in SLE is an unusual clinical event, ithas been suggested that an activation of the coagulation system to somedegree occurs in the majority of the patients with active SLE (16).…”

Activation of the Coagulation System in Connective Tissue Diseases:A Study of[125I]Fibrinogen Clearance

“…Activation of the coagulation system in connective tissue diseases has been reported and suggested to play a critical role in the complex mechanism of immune vasculitis (8, 9,12,15).…”

“…Schematic representation of possible relationships between immunologic factors and activation of coagulation system. including 12 with active disease (7 with nephritis) and 4 cases in clinically inactive phase:15 patients with Rheumatoid Arthritis (RA) including 8 with active disease (2 seronegative) and 7 cases in remission phase: 9 patients with Progressive Systemic Sclerosis (PSS); 4 patients with Acute Polymyositis (PM); 4 patients with Mixed Connective Tissue Disease (MCTD). Clearance was then evaluated with the usual T / 2 method.…”